The mitochondrial messenger for metabolic vitality
Injection · 503A Compounding
Educational content. This page describes MOTS-c for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.
Reduces myostatin expression and downstream atrophy signaling, helping preserve lean mass during aging or caloric restriction.[5]
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by a short stretch of mitochondrial DNA inside the 12S rRNA gene. Dr. Changhan Lee and colleagues at USC described it in 2015 as one of the first mitochondrial-derived peptides shown to act like a metabolic hormone, with skeletal muscle as its main target.
MOTS-c is naturally produced, with levels that fluctuate in response to exercise, diet, and aging. Circulating MOTS-c increases after exercise and declines with age, suggesting it may mediate exercise's metabolic benefits.
MOTS-c works mainly through AMPK, the cell's master energy sensor, but it reaches it indirectly. It interferes with the folate cycle and the purine-building pathway attached to it, which lets the natural AMPK activator AICAR build up. That AMPK activation pushes skeletal muscle to take up more glucose, burn more fat, and run more efficiently.
Uniquely, MOTS-c can translocate from the cytoplasm to the nucleus during metabolic stress, directly modulating gene expression through antioxidant response elements (AREs).
It also reduces myostatin expression and attenuates muscle atrophy signaling, helping preserve lean mass during aging or caloric restriction.
The mitochondrial messenger for metabolic vitality
MOTS-c is a mitochondrial-encoded peptide that switches on AMPK, the cell's main energy sensor, by blocking the folate and purine pathways so the natural activator AICAR accumulates. Under metabolic stress it moves into the nucleus within minutes to help steer stress-response genes. In animal studies this improves glucose handling and fat burning and helps preserve muscle and mitochondrial function.
MOTS-c prevented diet-induced obesity and both age-related and diet-induced insulin resistance, improving glucose tolerance. It had no effect on the body weight of normal-diet mice.
Lee C, Zeng J, Drew BG, et al. · Cell Metab, 21(3):443-454 (2015) · PubMed
MOTS-c lowered glucose and insulin and shifted plasma lipid metabolites away from the obese/diabetic pattern, consistent with improved insulin sensitivity.
Kim SJ, et al. · Physiological Reports, 7(13):e14171 (2019) · PubMed
In old mice, MOTS-c roughly doubled running endurance and improved grip strength and gait. In 10 healthy men, a single exercise bout raised muscle MOTS-c about 12-fold, the strongest human signal to date.
Reynolds JC, Lai RW, Woodhead JST, et al. · Nat Commun, 12(1):470 (2021) · PubMed
MOTS-c reduced myostatin and downstream atrophy markers (MuRF1, Atrogin-1).
Kumagai H, Coelho AR, Wan J, et al. · Am J Physiol Endocrinol Metab, 320(4):E680-E690 (2021) · PubMed
Three weeks of MOTS-c restored heart mitochondrial respiration, lowered fasting glucose, and reduced cardiac hypertrophy.
Pham J, et al. · Frontiers in Physiology, 16:1602271 (2025) · PubMed
start low, go slow
Subcutaneous Injection
Subcutaneous Injection: No standardized or FDA-established human dose; these figures reflect clinic and community practice, not controlled trials
No human trial has established a MOTS-c dose. The figures here come from clinic and community practice, not controlled studies, and are not FDA-established.
Practitioners typically start at 5 mg 3x/week and assess tolerance.
Some recommend timing around training sessions due to exercise-mimetic properties.
MOTS-c is a peptide the body's own mitochondria make, and animal studies have not flagged major toxicity. Formal safety studies of injected MOTS-c in people have not been done.
No human trial has shown that taking MOTS-c is safe or effective. Nearly all evidence comes from mouse and rat studies; the one solid human finding is that exercise raises the body's own MOTS-c.
Because MOTS-c lowers glucose in animal models, there is a theoretical hypoglycemia risk alongside diabetes medication. AMPK's mixed role in cancer biology is a second theoretical caution.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| MOTS-c | Metabolic Optimization & Anti-Aging | Injection (3-5x weekly) | 4–8 weeks | Mitochondrial-encoded peptide that mimics aspects of exercise via AMPK and nucleus signaling; human evidence is still observational |
| SS-31 (Elamipretide) | Mitochondrial restoration and rare mitochondrial disease | Subcutaneous injection (daily); IV in trials | Ongoing daily dosing | The first FDA-approved mitochondria-targeted therapeutic; binds cardiolipin on the inner mitochondrial membrane to support electron transport efficiency |
| Semaglutide | Weight Management & Metabolic Health | Injection (weekly), Oral (daily) | Ongoing | The most clinically validated GLP-1 medicine, with outcomes data spanning weight, heart, kidney, and liver disease |
| Tirzepatide | Weight Loss & Type 2 Diabetes | Injection (weekly) | Ongoing | Only dual GIP/GLP-1 agonist; the deepest weight loss of any approved obesity drug, up to about 21% of body weight |
| Tesamorelin | Visceral Fat & GHRH Signaling | Subcutaneous Injection | Ongoing daily | The only FDA-approved GHRH analog, with Phase III data in over 800 patients, documented liver-fat reduction, and physiologic pulsatile GH release |
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Listed in Category 2 since September 2023. FDA has not identified any human exposure data for drug products containing MOTS-c via any route. Immunogenicity and impurity concerns cited. Not eligible for compounding.
Placed in 503A Category 2 with significant safety risks identified
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into MOTS-c? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA GLP-1 receptor agonist that slows gastric emptying and reduces appetite signaling.
Approved as Ozempic and Wegovy for diabetes and chronic weight management; compounding increasingly restricted.
A dual GIP and GLP-1 receptor agonist developed for diabetes and weight management.
Approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
A stabilized 44-residue GHRH analog that stimulates endogenous growth hormone secretion.
FDA-approved as Egrifta for HIV-associated lipodystrophy; strongest clinical evidence of the GHRH analog family.
“Specializing in Aesthetics and Wellness ”
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering MOTS-c.